No Data
Live Stock News: Market Waiting to See if the President Says Something Exciting Today
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,059
RBC Capital Sticks to Their Buy Rating for Regeneron (REGN)
Wall Street Today: Does Anyone Have the Cash for Stargates
Live Stock: Stargate Rivals the Scale of the Manhattan Project, Musk Said it's a Pipe Dream
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,059 From $1,184, Maintains Outperform Rating
Growth Investor27 : I own a lot & will buy more
DazzlerAus : agree but nothing seems to help